{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:11:32Z","timestamp":1787317892128,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Astellas Pharma, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12325-023-02433-0","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T11:08:19Z","timestamp":1675768099000},"page":"1546-1559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct02021318","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02052310","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02273726","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02174731","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-7229","authenticated-orcid":false,"given":"Jonathan","family":"Barratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dellanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Portoles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Choukroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Dimkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"issue":"Suppl 1","key":"2433_CR1","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.2215\/CJN.04360709","volume":"4","author":"RL Wingard","year":"2009","unstructured":"Wingard RL, Chan KE, Lazarus JM, Hakim RM. The \u201cright\u201d of passage: surviving the first year of dialysis. Clin J Am Soc Nephrol. 2009;4(Suppl 1):S114\u201320.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2433_CR2","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","volume":"36","author":"R Provenzano","year":"2021","unstructured":"Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021;36:1717\u201330.","journal-title":"Nephrol Dial Transplant"},{"key":"2433_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1440-1797.2007.00810.x","volume":"12","author":"DW Johnson","year":"2007","unstructured":"Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007;12:321\u201330.","journal-title":"Nephrology (Carlton)"},{"key":"2433_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584\u201390.","journal-title":"N Engl J Med"},{"key":"2433_CR5","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019\u201332.","journal-title":"N Engl J Med"},{"key":"2433_CR6","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085\u201398.","journal-title":"N Engl J Med"},{"key":"2433_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1203165","volume":"368","author":"S Fishbane","year":"2013","unstructured":"Fishbane S, Schiller B, Locatelli F, EMERALD Study Groups, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368:307\u201319.","journal-title":"N Engl J Med"},{"key":"2433_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","volume":"74","author":"LA Szczech","year":"2008","unstructured":"Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791\u20138.","journal-title":"Kidney Int"},{"key":"2433_CR9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S0272-6386(04)01086-8","volume":"44","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866\u201376.","journal-title":"Am J Kidney Dis"},{"key":"2433_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2215\/CJN.04601007","volume":"3","author":"RD Kilpatrick","year":"2008","unstructured":"Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1077\u201383.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2433_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/nep.13560","volume":"24","author":"L Zhao","year":"2019","unstructured":"Zhao L, Hu C, Cheng J, Zhang P, Jiang H, Chen J. Haemoglobin variability and all-cause mortality in haemodialysis patients: a systematic review and meta-analysis. Nephrology (Carlton). 2019;24:1265\u201372.","journal-title":"Nephrology (Carlton)"},{"key":"2433_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143348","volume":"10","author":"MN Bae","year":"2015","unstructured":"Bae MN, Kim SH, Kim YO, et al. Association of erythropoietin-stimulating agent responsiveness with mortality in hemodialysis and peritoneal dialysis patients. PLoS One. 2015;10: e0143348.","journal-title":"PLoS One"},{"key":"2433_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381:1011\u201322.","journal-title":"N Engl J Med"},{"key":"2433_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381:1001\u201310.","journal-title":"N Engl J Med"},{"key":"2433_CR15","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M. Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney Int Rep. 2021;6:1810\u201328.","journal-title":"Kidney Int Rep"},{"key":"2433_CR16","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2019060623","volume":"31","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol. 2020;31:1628\u201339.","journal-title":"J Am Soc Nephrol"},{"key":"2433_CR17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","volume":"36","author":"E Shutov","year":"2021","unstructured":"Shutov E, Sulowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant. 2021;36:1629\u201339.","journal-title":"Nephrol Dial Transplant"},{"key":"2433_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","volume":"6","author":"DW Coyne","year":"2021","unstructured":"Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6:624\u201335.","journal-title":"Kidney Int Rep"},{"key":"2433_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","volume":"32","author":"S Fishbane","year":"2021","unstructured":"Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol. 2021;32:737\u201355.","journal-title":"J Am Soc Nephrol"},{"key":"2433_CR20","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","volume":"38","author":"B Csiky","year":"2021","unstructured":"Csiky B, Schomig M, Esposito C, et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Adv Ther. 2021;38:5361\u201380.","journal-title":"Adv Ther"},{"key":"2433_CR21","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","volume":"6","author":"C Charytan","year":"2021","unstructured":"Charytan C, Manllo-Karim R, Martin ER, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021;6:1829\u201339.","journal-title":"Kidney Int Rep"},{"key":"2433_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","volume":"33","author":"S Fishbane","year":"2022","unstructured":"Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol. 2022;33:850\u201366.","journal-title":"J Am Soc Nephrol"},{"key":"2433_CR23","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","volume":"36","author":"J Barratt","year":"2021","unstructured":"Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021;36:1616\u201328.","journal-title":"Nephrol Dial Transplant"},{"key":"2433_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"KA Hicks","year":"2015","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC\/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015;66:403\u201369.","journal-title":"J Am Coll Cardiol"},{"key":"2433_CR25","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","volume":"38","author":"J Barratt","year":"2021","unstructured":"Barratt J, Sulowicz W, Schomig M, et al. Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies. Adv Ther. 2021;38:5345\u201360.","journal-title":"Adv Ther"},{"key":"2433_CR26","unstructured":"US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry Diabetes Mellitus\u2014Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. December 2008. https:\/\/www.fda.gov\/media\/71297\/download. Accessed 22 Apr 2022."},{"key":"2433_CR27","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Reflection paper on assessment of cardiovascular safety profile of medicinal products. 25 Feb 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-assessment-cardiovascular-safety-profile-medicinal-products_en.pdf. Accessed 22 Apr 2022."},{"key":"2433_CR28","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2215\/CJN.16191020","volume":"16","author":"R Provenzano","year":"2021","unstructured":"Provenzano R, Szczech L, Leong R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials. Clin J Am Soc Nephrol. 2021;16:1190\u2013200.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2433_CR29","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","volume":"384","author":"KU Eckardt","year":"2021","unstructured":"Eckardt KU, Agarwal R, Aswad A, ASCEND-ND Study Group, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021;384:1601\u201312.","journal-title":"N Engl J Med"},{"key":"2433_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1053\/j.ajkd.2011.11.038","volume":"59","author":"MP Lilly","year":"2012","unstructured":"Lilly MP, Lynch JR, Wish JB, et al. Prevalence of arteriovenous fistulas in incident hemodialysis patients: correlation with patient factors that may be associated with maturation failure. Am J Kidney Dis. 2012;59:541\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2433_CR31","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/ndt\/gfm474","volume":"23","author":"H Guo","year":"2008","unstructured":"Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients\u2013the United States Renal Data System. Nephrol Dial Transplant. 2008;23:680\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"2433_CR32","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, McMurray JJV, ASCEND-ND Study Group, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med. 2021;385:2313\u201324.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02433-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02433-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02433-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T06:38:32Z","timestamp":1680503912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02433-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2433"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02433-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}